L7H-96212-40156 · OpenVSafe

Timeline

Registration Vaccinations Survey responses Call reports Cases without a report Call attempts Call successful Pregnancy survey

2021-04-16
Registered in v-safe
2021-04-16
Dose 1 — Pfizer-BioNTech
2021-04-16
Health check-in — day 0, dose 1
Feeling: Fair · Site: Pain · Muscle or body aches, Nausea, Abdominal pain · Be unable to work, Be unable to do your normal daily activities

Adult check-in
2021-04-16
Report sent to call center — day 0, dose 1
Be unable to work · Be unable to do your normal daily activities

1 call case(s)
2021-04-17
Survey response — days 1–6 daily, dose 1
MedDRA: Blister, Rash — Feeling: Fair · Site: Pain · Joint pains, Fatigue or tiredness, Nausea, Rash, not including the immediate area around the injection site · Be unable to work, Be unable to do your normal daily activities

Free text: Blisters in the rash

MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
2021-04-17
Report sent to call center — days 1–6 daily, dose 1
Be unable to work · Be unable to do your normal daily activities

1 call case(s)
2021-04-18
Survey response — days 1–6 daily, dose 1
MedDRA: Blister, Rash — Feeling: Good · Headache, Muscle or body aches, Fatigue or tiredness, Rash, not including the immediate area around the injection site

Free text: Blister and pain at site of rash

MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
2021-04-19
Survey response — days 1–6 daily, dose 1
MedDRA: Blister, Pain, Rash — Feeling: Good · Headache, Fatigue or tiredness, Rash, not including the immediate area around the injection site

Free text: Blisters and pain at rash site

MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
2021-04-20
Survey response — days 1–6 daily, dose 1
MedDRA: Injection site reaction, Rash vesicular — Feeling: Good · Rash, not including the immediate area around the injection site

Free text: Blisters at rash site

MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
2021-05-11
Dose 2 — Pfizer-BioNTech
2021-05-12
Survey response — days 1–6 daily, dose 2
MedDRA: Unevaluable event — Feeling: Poor · Site: Pain · Joint pains, Muscle or body aches, Abdominal pain · Be unable to work, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultation

Free text: Vaginal spotting and cramping

MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
2021-05-12
Report sent to call center — days 1–6 daily, dose 2
Be unable to work · Be unable to do your normal daily activities · Get care from a doctor or other healthcare professional

1 call case(s)
2021-05-14
Call 1 — Left Voicemail

Vaccinations

Dose	Date	Manufacturer	Co-administered
1	2021-04-16	Pfizer-BioNTech
2	2021-05-11	Pfizer-BioNTech

Call center

3 call center cases

1 unsuccessful · 2 priority 2/3 (triaged and no follow up)

See the call center timeline

Free text

Release 7 — days 1–6 daily, dose 1

2021-04-17

Systemic reaction (other): Blisters in the rash

2021-04-18

Systemic reaction (other): Blister and pain at site of rash

2021-04-19

Systemic reaction (other): Blisters and pain at rash site

2021-04-20

Systemic reaction (other): Blisters at rash site

Release 8 — days 1–6 daily, dose 2

2021-05-12

Systemic reaction (other): Vaginal spotting and cramping

Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".

MedDRA terms by release

Field	Preferred term	2021-09	2023-04	2024-11
SRO	Blister	✓	✓	✓
SRO	Injection site reaction	✓	✓	✓
SRO	Pain	✓	✓	✓
SRO	Rash	✓	✓	✓
SRO	Rash vesicular	✓	✓	✓
SRO	Unevaluable event	✓	✓	✓

✓ active code · ○ coded but marked inactive · blank = not in that release